Table 1 Univariate and multivariate Cox regression analyses for DFS in breast cancer and per molecular subtype.
From: The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
DFS | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
N | HR [95% CI] | p-value | N | HR [95% CI] | p-value | ||
All breast cancers | |||||||
Patients’ age | >50 vs. ≤50 | 4707 | 0.81 [0.72–0.91] | 3.20E−04 | 2265 | 0.92 [0.76–1.11] | 0.384 |
Pathological tumor type | Lobular vs. ductal | 3602 | 0.95 [0.75–1.21] | 2.69E−04 | 2265 | 1.45 [1.08–1.95] | 1.28E−02 |
Other vs. ductal | 0.61 [0.47–0.77] | 2265 | 0.65 [0.48–0.88] | 5.57E−03 | |||
Pathological grade | 2 vs. 1 | 4018 | 1.68 [1.35–2.09] | 2.46E−22 | 2265 | 1.12 [0.79–1.59] | 0.512 |
3 vs. 1 | 2.56 [2.06–3.17] | 2265 | 1.06 [0.74–1.53] | 0.738 | |||
Pathological axillary lymph node status | Positive vs. negative | 5165 | 1.63 [1.47–1.82] | 3.16E−19 | 2265 | 1.83 [1.49–2.23] | 4.80E−09 |
Pathological tumor size | pT2 vs. pT1 | 4719 | 1.59 [1.40–1.80] | 1.68E−22 | 2265 | 1.46 [1.23–1.73] | 1.92E−05 |
pT3 vs. pT1 | 2.58 [2.10–3.17] | 2265 | 2.11 [1.56–2.87] | 1.64E−06 | |||
Adjuvant chemotherapy | yes vs. no | 4442 | 1.52 [1.33–1.73] | 6.02E−10 | 2265 | 1.14 [0.90–1.43] | 0.272 |
Adjuvant hormone therapy | yes vs. no | 4382 | 0.77 [0.68–0.87] | 2.95E−05 | 2265 | 0.71 [0.58–0.86] | 4.89E−04 |
PAM50-derived molecular subtype | ERBB2 vs. Basal | 6035 | 1.11 [0.96–1.27] | 1.40E−45 | 2265 | 1.23 [0.97–1.55] | 0.088 |
Luminal A vs. Basal | 0.45 [0.39–0.52] | 2265 | 0.6 [0.44–0.82] | 1.43E−03 | |||
Luminal B vs. Basal | 0.85 [0.75–0.97] | 2265 | 1.08 [0.84–1.40] | 0.536 | |||
Normal vs. Basal | 0.47 [0.39–0.57] | 2265 | 0.67 [0.46–0.98] | 4.03E−02 | |||
CINSARC classes | High vs. Low-risk | 6035 | 1.80 [1.64–1.98] | 9.44E−34 | 2265 | 1.19 [0.97–1.46] | 0.095 |
Per molecular subtype | |||||||
CINSARC classes in Luminal A | High vs. Low-risk | 1753 | 1.40 [1.03–1.91] | 3.40E−02 | |||
CINSARC classes in Luminal B | High vs. Low-risk | 1438 | 1.43 [1.18–1.73] | 2.18E−04 | |||
CINSARC classes in Basal | High vs. Low-risk | 1241 | 1.03 [0.76–1.40] | 0.841 | |||
CINSARC classes in ERBB2-enriched | High vs. Low-risk | 911 | 1.01 [0.79–1.30] | 0.925 | |||
CINSARC classes in Normal-like | High vs. Low-risk | 692 | 1.27 [0.83–1.92] | 0.269 | |||
